BrownEL, EssigmannHT, and PascualDW: Original antigenic sin: The downside of immunological memory and implications for COVID-19. mSphere, 2021; 6:e00056-21.
2.
StamperCT, and WilsonPC: What are the primary limitations in B-cell affinity maturation, and how much affinity maturation can we drive with vaccination? Is affinity maturation a self-defeating process for eliciting broad protection?. Cold Spring Harb Perspect Biol, 2018; 10:a028803.
3.
RijkersGT, and van OverveldFJ: The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination. Clin Immunol Commun, 2021; 1:13–16.
4.
Kieber-EmmonsT, BrownE, NaraP, and KohlerH: Expert panel discussion on antigenic sin. Monoclon Antib Immunodiagn Immunother, 2021; 40:203–209.
5.
LiuT, ZhangY, LiuY, WangY, JiaH, KangM, LuoX, CaballeroD, GonzalezJ, SherwoodL, NunezV, WangD, WoodsA, SchultzPG, and WangF: Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists. Proc Natl Acad Sci U S A, 2015; 112:1356–1361.
6.
ZanettiM, FilaciG, LeeRH, GuercioPd, RossiF, BacchettaR, StevensonF, BarnabaV, and BillettaR: Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif. EMBO J, 1993; 12:4375–4384.
7.
PollardAJ, and BijkerEM: A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol, 2021; 21:83–100.
8.
KimJH, DavisWG, SambharaS, and JacobJ: Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A, 2012; 109:13751–13756.
9.
BodeC, ZhaoG, SteinhagenF, KinjoT, and KlinmanDM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines, 2011; 10:499–511.
10.
ShuY, and McCauleyJ: GISAID: Global initiative on sharing all influenza data—From vision to reality. Eurosurveillance, 2017; 22:30494.
11.
ElbeS, and Buckland-MerrettG: Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall, 2017; 1:33–46.
